Compare · IZTC vs RVMD
IZTC vs RVMD
Side-by-side comparison of Invizyne Technologies Inc. (IZTC) and Revolution Medicines Inc. (RVMD): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both IZTC and RVMD operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- RVMD carries a market cap of $45.31B.
- RVMD has hit the wire 11 times in the past 4 weeks while IZTC has been quiet.
- RVMD has more recent analyst coverage (25 ratings vs 0 for IZTC).
- Company
- Invizyne Technologies Inc.
- Revolution Medicines Inc.
- Price
- -
- -
- Market cap
- -
- $45.31B
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2024
- 2020
- News (4w)
- 0
- 11
- Recent ratings
- 0
- 25
Revolution Medicines Inc.
Revolution Medicines, Inc., a clinical-stage precision oncology company, focuses on developing therapies to inhibit frontier targets in RAS-addicted cancers. The company is developing RMC-4630, an inhibitor of SHP2, which is in Phase 1/2 clinical trial for the treatment of solid tumors, such as gynecologic and colorectal cancer tumors. It also develops RMC-5845, a selective inhibitor of SOS1, a protein that converts RAS (OFF) to RAS (ON) in cells; and RMC-5552, a hyperactivated selective inhibitor of mTORC1 signaling in tumors. In addition, the company is developing RMC-6291, a mutant-selective inhibitor of KRASG12C(ON) and NRASG12C(ON); and RMC-6236, a RAS-selective inhibitor of multiple RAS(ON) variants. Further, it develops RAS(ON) Inhibitors targeting KRASG13C(ON) and KRASG12D(ON). Revolution Medicines, Inc. has a collaboration agreement with Sanofi for the research and development of SHP2 inhibitors, including RMC-4630. The company was incorporated in 2014 and is headquartered in Redwood City, California.
Latest IZTC
- Rebranding Invizyne to eXoZymes Signifies a Sustainable Paradigm Shift in Chemical Production Leveraging AI-Engineered Enzymes
- Invizyne Technologies Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
- Invizyne Technologies Announces Name Change to eXoZymes, Inc. and New Ticker Symbol
- Chief Executive Officer Heltzen Michael bought $20,345 worth of shares (1,888 units at $10.78), increasing direct ownership by 95% to 3,872 units (SEC Form 4)
- Chief Executive Officer Heltzen Michael bought $22,022 worth of shares (1,984 units at $11.10) (SEC Form 4)
- SEC Form 3 filed by new insider Bell Lon E
- Invizyne Technologies Selected for $2 Million Project to Advance Sustainable Aviation Fuel Capabilities
- SEC Form SC 13D filed by Invizyne Technologies Inc.
- SEC Form SC 13D filed by Invizyne Technologies Inc.
- SEC Form SC 13D filed by Invizyne Technologies Inc.
Latest RVMD
- General Counsel Cislini Jeff exercised 56,280 shares at a strike of $20.00 and sold $11,904,247 worth of shares (56,894 units at $209.24) as part of a pre-agreed trading plan, decreasing direct ownership by 1% to 55,907 units (SEC Form 4)
- Officer Goldsmith Mark A exercised 80,000 shares at a strike of $4.73 and sold $17,991,107 worth of shares (86,000 units at $209.20) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 144 filed by Revolution Medicines Inc.
- SEC Form 144 filed by Revolution Medicines Inc.
- SEC Form 144 filed by Revolution Medicines Inc.
- Amendment: SEC Form SCHEDULE 13G/A filed by Revolution Medicines Inc.
- SEC Form SCHEDULE 13G filed by Revolution Medicines Inc.
- BeOne Medicines and Revolution Medicines Announce Clinical Development and Regional Commercialization Collaboration
- SEC Form 10-Q filed by Revolution Medicines Inc.
- Revolution Medicines Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits